nysebmy
Bristol-Myers Squibb (NYSE:BMY) posted a modest gain after a double beat on earnings.The company continues to display strong fundamentals and a robust pipeline.Although growth investors may not be pleased, Bristol-Myers Squibb stock remains a strong value stock.Bristol-Myers Squibb Co (NYSE:BMY) posted a small gain after an earnings report; the company beat its top and bottom lines. The pharmaceutical company delivered earnings per share (EPS) of $1.99 on revenue of $11.22 billion. That was better than the analyst forecast for $1.83 EPS on revenue of $11.18 billion. Q3 2022 hedge fund letters,...
ValueWalk
On the heels of OxyContin maker Purdue Pharma asking a federal judge to approve a $6 billion nationwide settlement due to the overdose and addiction crisis, a new company will form following the U.S. Bankruptcy Court chapter 11 plan of reorganization. The resulting company is known as Knoa Pharma and profits will be used to fight an opioid crisis that has been linked to the deaths of more than 500,000 Americans over the past two decades. Despite the devastating headlines linked to pharmaceuticals, you can still point to dozens of reasons to invest in pharmaceuticals. The global pharmaceuticals...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら